Last 563.30
Change Today 0.00 / 0.00%
Volume 0.0
RDHL On Other Exchanges
Tel Aviv
As of 10:24 AM 02/26/15 All times are local (Market data is delayed by at least 15 minutes).

redhill biopharma ltd (RDHL) Snapshot

Previous Close
Day High
Day Low
52 Week High
06/12/14 - $680.00
52 Week Low
11/18/14 - $295.00
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for REDHILL BIOPHARMA LTD (RDHL)

Related News

No related news articles were found.

redhill biopharma ltd (RDHL) Related Businessweek News

No Related Businessweek News Found

redhill biopharma ltd (RDHL) Details

RedHill Biopharma Ltd., an Israeli biopharmaceutical company, focuses on the development and acquisition of late clinical-stage, proprietary drugs for the treatment of inflammatory and gastrointestinal diseases, including gastrointestinal cancers. The company’s pipeline of therapeutic candidates include RHB-105 intended for the eradication of Helicobacter pylori infection that is under Phase III study; RHB-104 for the treatment of Crohn's disease, which is under Phase III study; BEKINDA for the prevention of chemotherapy and radiotherapy induced nausea and vomiting, and gastroenteritis and gastritis that is under phase III study; and RHB-106 intended for the preparation and cleansing of the gastrointestinal tract. Its pipeline of therapeutic candidates also comprise MESUPRON, a urokinase-type plasminogen activator inhibitor targeting gastrointestinal and other solid tumor cancers that has completed Phase II-stage; RP101, a Hsp27 inhibitor for the treatment of pancreatic and other gastrointestinal cancers; RIZAPORT, an oral thin film formulation of rizatriptan for acute migraines; and RHB-101 for the treatment of hypertension, heart failure, and left ventricular dysfunction. The company was founded in 2009 and is based in Tel Aviv, Israel.

8 Employees
Last Reported Date: 02/25/14
Founded in 2009

redhill biopharma ltd (RDHL) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

redhill biopharma ltd (RDHL) Key Developments

RedHill Biopharma Ltd. to Report Q4, 2014 Results on Feb 26, 2015

RedHill Biopharma Ltd. announced that they will report Q4, 2014 results on Feb 26, 2015

RedHill Biopharma Ltd., Q4 2014 Earnings Call, Feb 26, 2015

RedHill Biopharma Ltd., Q4 2014 Earnings Call, Feb 26, 2015

RedHill Biopharma Ltd. Presents at Life Sciences Israel(TM) 2015, Feb-19-2015 11:30 AM

RedHill Biopharma Ltd. Presents at Life Sciences Israel(TM) 2015, Feb-19-2015 11:30 AM. Venue: Dan Panorama Hotel, Charles Clore Park, Tel Aviv 68012, Israel. Speakers: Dror Ben-Asher, Chairman and Chief Executive Officer.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RDHL:IT 563.30 0.00

RDHL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for RDHL.
View Industry Companies

Industry Analysis


Industry Average

Valuation RDHL Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact REDHILL BIOPHARMA LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at